Khosla Ventures

Science is a startup company that develops technologies for a range of serious unmet medical needs.

C the Signs is a healthcare technology company that has developed a cancer prediction system. This system enables general practitioners (GPs) to swiftly assess combinations of signs, symptoms, and risk factors during consultations, supporting them in recommending appropriate investigations or urgent referrals for patients suspected of having cancer.

Rad AI develops an artificial intelligence platform that automates report generation for radiologists. Its solution integrates with existing workflows, automating repetitive tasks to enhance efficiency, reduce burnout, and improve patient care.

Neurode develops a non-invasive wearable headset and companion software to treat and monitor ADHD-related symptoms by delivering electrical stimulation to balance brain activity, targeting cognitive functions such as working memory, attention, and impulse control. The drug-free approach supports medical professionals in improving cognitive performance, while the paired app tracks progress and shares data with clinicians for ongoing assessment and adjustment of treatment.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Rad AI develops an artificial intelligence platform that automates report generation for radiologists. Its solution integrates with existing workflows, automating repetitive tasks to enhance efficiency, reduce burnout, and improve patient care.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Founded in Bengaluru, India in 2016, CureSkin develops AI-powered software that analyzes skin issues via mobile photos. It recommends products, dermatologists, and personalized treatment plans for clients.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Founded in London in 2017, Limbic specializes in developing software solutions for mental health. They create AI-driven agents to assist in patient intake, triage, screening, and therapy, aiming to enhance the efficiency of healthcare providers and improve patient outcomes.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Helping people with chronic conditions mitigate their symptoms.

Gather Health is an international healthcare technology company dedicated to empowering chronic disease patients to enhance their health. The company develops mobile and cloud-based healthcare applications that utilize cutting-edge medical and behavioral research to motivate and educate patients. By connecting physicians, patients, their families, and communities, Gather Health aims to provide continuous and holistic care that leads to improved health outcomes. The rise in chronic diseases such as obesity, diabetes, and hypertension has created a pressing need for effective patient care solutions, especially given the shortage of healthcare providers. Gather Health's flagship product, the Gather Health Diabetes platform, is currently utilized by physicians and patients in various cities across Hong Kong and India, including Mumbai and Bangalore, demonstrating positive health outcomes for users. Headquartered in Hong Kong, with additional offices in Beijing, New York, and India, the company boasts a diverse team of clinicians, health experts, interaction designers, and engineers experienced in the global healthcare landscape.

Tachyon Therapeutics develops innovative compounds to enhance cancer treatments. It is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of its lead compound, TACH101.

IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.

Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.

Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.

NextVivo is a biotechnology company developing an immune organoid technology platform. This platform aims to transform drug development by accelerating the creation of safer, more effective therapies. It achieves this by generating and testing therapies in human-derived models that mimic the body's natural immune response.

Robin Healthcare, Inc. is a healthcare technology company founded in 2017 and headquartered in Berkeley, California, with an additional office in Austin, Texas. The company specializes in developing innovative solutions for the medical industry, including a smart assistant device, clinical documentation solutions, and services for order and medication entry, chart review, billing and coding, and referral management. Robin Healthcare provides comprehensive medical scribe services designed to alleviate administrative burdens on healthcare providers, thereby enhancing the doctor-patient experience. By integrating technology and trained medical scribes directly into electronic medical records, the company aims to streamline workflows and allow physicians to focus more on patient care.

Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Pearl Bio is a synthetic biology company that leverages its proprietary platform to create novel biologics and biomaterials. By engineering genomes and ribosomes, the company enables scientists to explore diverse chemistries and advance treatments for genetic or acquired diseases.

Founded in 2018, Lightship aims to enhance health equity globally by transforming clinical trials. It combines digital health innovations, technology, remote care, and high-quality clinical research to make studies more accessible and offer choices, keeping patients at the core of its work.

Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Connie Health assists older Americans in making informed decisions about their healthcare by providing medical advisory services through a technology platform paired with local Medicare experts. They help individuals optimize prescription costs, find healthcare providers, and navigate insurance plan benefits.

IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.

Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.

Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.

StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.

Quadrant Eye is an innovative company focused on transforming the field of online eye care. It has developed a platform that facilitates instant and reliable remote eye examinations, allowing patients to screen, diagnose, and manage both low-acuity and chronic eye conditions from the comfort of their homes. The platform addresses a range of eye health issues, including cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. By providing accessible services for conditions such as diabetic eye disease and nearsightedness, Quadrant Eye aims to enhance patient care and streamline the treatment process for various ocular health concerns.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Lumiata is a predictive health analytics company that applies artificial intelligence to healthcare data to deliver real-time, patient-level predictions. It builds a medical graph to organize symptoms, diagnoses, procedures and medications, enabling risk-bearing organizations such as payers, hospital networks, and population health programs to forecast health trajectories, cost, and care needs. The Lumiata Risk Matrix provides time-based predictions with explanations of medical reasoning. The platform combines big data, clinical knowledge, and proprietary intellectual property drawn from over 120 million patient records to support use cases like underwriting and care management. Founded in 2013 and based in San Mateo, California, Lumiata serves providers, payers, and digital health companies, enabling predictive analytics at scale while protecting privacy.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.

Focal Medical is a biopharmaceutical company focused on developing targeted therapeutic delivery systems for cancer. It leverages an innovative and patent-protected platform to create therapies that actively direct chemotherapeutics to tumor sites, aiming to improve efficacy and reduce systemic exposure. The lead program targets pancreatic cancer by delivering gemcitabine directly to the pancreas through non-circulatory pathways. The company also develops drug-delivery technologies for solid tumors that are difficult to treat with systemic therapy, including approaches that combine iontophoresis with implantable delivery systems to achieve precise chemotherapy delivery. Headquartered in Cary, North Carolina, Focal Medical emphasizes advancing treatments with targeted delivery to support quicker patient recovery and better tolerability.

IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.

Caption Health, Inc. is a technology company specializing in artificial intelligence software designed to enhance the acquisition and interpretation of ultrasound exams. Its flagship product, Caption AI, serves as an AI-guided medical imaging acquisition system that assists healthcare providers by offering real-time guidance, automating quality assessments, and interpreting ultrasound images to ensure diagnostic accuracy. Founded in 2013 and headquartered in Brisbane, California, Caption Health was previously known as Bay Labs, Inc. The company aims to scale its commercial operations and further develop its AI technology platform, intending to broaden the application of Caption AI across various clinical settings as adoption increases among healthcare practitioners.

Kernel, a neuroscience company founded in 2016 and headquartered in Los Angeles, California, develops advanced brain-recording technologies aimed at enhancing human cognition. The company specializes in creating a non-invasive brain interface that captures neural signals with quality comparable to traditional imaging methods like fMRI and MEG, while being as user-friendly as EEG. Kernel's primary focus is on addressing dysfunctions linked to neurodegenerative diseases, offering neuroprosthetics that can mimic, repair, and improve cognitive functions. Additionally, the company provides access to brain imaging devices that enable remote experimentation, thereby furthering the understanding and treatment of neurological disorders.

HeartVista is a medical technology company that provides one-click diagnostic imaging. It brought in machine learning to make the scanning process faster, easier, and more consistent. Its platform leverages existing scanners and contains all of the mri tools needed for a comprehensive cardiac examination, with just one click.

Yes Health designs a mobile application offering personalized nutrition, fitness, and diabetes-prevention advice. Its team of physicians, health coaches, and engineers creates engaging programs for users to adopt healthier lifestyles, prevent diabetes onset, and manage symptoms effectively.

Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.

Founded in 2018, Lightship aims to enhance health equity globally by transforming clinical trials. It combines digital health innovations, technology, remote care, and high-quality clinical research to make studies more accessible and offer choices, keeping patients at the core of its work.

Connie Health assists older Americans in making informed decisions about their healthcare by providing medical advisory services through a technology platform paired with local Medicare experts. They help individuals optimize prescription costs, find healthcare providers, and navigate insurance plan benefits.

Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Digi-Prex is a healthcare company that operates a monthly medication delivery platform focused on chronic disease management. Founded in 2019 and headquartered in Hyderabad, India, with an additional office in San Francisco, California, the company enables patients to manage their conditions more effectively. Digi-Prex provides a subscription service that offers discounted medications based on prescriptions uploaded by patients. The platform ensures regular delivery of these medicines from local pharmacies, making it a cost-effective solution for patients. In addition to medication delivery, Digi-Prex offers a comprehensive service tailored to the unique needs of each patient, creating a one-stop solution for managing chronic health conditions.

Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.

Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.

Probably Genetic is a company that provides genetic testing services to diagnose rare genetic conditions, including those often initially misdiagnosed as autism spectrum disorder. It enables at-home saliva sample collection and performs comprehensive DNA sequencing analysis, accompanied by personalized counseling to help patients and families obtain accurate diagnoses and access relevant clinical treatments. By offering educational materials and streamlined testing, the company aims to shorten diagnostic journeys and support individuals who fall through gaps in the healthcare system.

Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.

DocBot, Inc. is an artificial intelligence technology company based in Irvine, California, specializing in gastrointestinal diseases. The company develops web-based applications for iOS and Android devices that serve as a clinical decision support system, aggregating patient information and providing cloud analytics to healthcare professionals. Its flagship product is built on the UltivisionAI software platform, which offers real-time image analysis, automated reporting, and analytical tools aimed at enhancing patient care and clinical workflows. By integrating various data sources from imaging systems to pathology requisitions, DocBot's platform aids physicians in detecting colorectal cancer and other gastrointestinal conditions, ultimately striving to improve healthcare outcomes and reduce patient risks.

BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.

Founded in Bengaluru, India in 2016, CureSkin develops AI-powered software that analyzes skin issues via mobile photos. It recommends products, dermatologists, and personalized treatment plans for clients.

StimScience develops non-invasive brain stimulation technologies, including transcranial direct current stimulation, transcranial alternating current stimulation, and transcranial random noise stimulation. Its NeuroMod tXES platform enables users to generate arbitrary waveforms for tailored tES applications. Founded in 2017 and based in Berkeley, California, StimScience focuses on commercializing neuroscience and sleep research into products and services for individuals, employers, and health plans. The team comprises leading sleep and neuroscience researchers and advisors, with early funding supporting the launch of Somnee, an advanced diagnostic and therapeutic product designed to help people fall asleep faster and achieve higher-quality restorative sleep. Sleep health is central to mental health, memory, learning, and physical well-being.

Loop Genomics develops long-read DNA sequencing technology that enables existing short-read instruments to perform high-throughput, phased, single-molecule sequencing. The company provides consumables and analysis tools to extend sequencing capabilities across research, diagnostics, agriculture-biotech, and industrial applications, allowing laboratories to access long-read sequencing without new platforms. Its technology supports full-length, phased sequencing of microbial communities to improve microbiome profiling by capturing all variable regions, and enables accurate phased sequencing of human leukocyte antigen genes to reduce diploid ambiguity for transplantation testing and association studies. In virology, it maps viral genetic variability at the quasi-species level to identify mutations and inform therapy and vaccine strategies. By delivering high-throughput, phased data with existing infrastructure, Loop Genomics clarifies complex genetic signals.

Higia Technologies, founded in 2016 and based in Mexico City, specializes in developing EVA, a non-invasive wearable device aimed at assessing breast cancer risk. This innovative device features tactile sensors that map the surface of the breast and its surrounding areas. By continuously monitoring changes in breast temperature, size, and weight through embedded biosensors, EVA empowers women to actively track their breast health. The company's focus is on making breast cancer risk assessment more accessible and user-friendly.

Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Lumiata is a predictive health analytics company that applies artificial intelligence to healthcare data to deliver real-time, patient-level predictions. It builds a medical graph to organize symptoms, diagnoses, procedures and medications, enabling risk-bearing organizations such as payers, hospital networks, and population health programs to forecast health trajectories, cost, and care needs. The Lumiata Risk Matrix provides time-based predictions with explanations of medical reasoning. The platform combines big data, clinical knowledge, and proprietary intellectual property drawn from over 120 million patient records to support use cases like underwriting and care management. Founded in 2013 and based in San Mateo, California, Lumiata serves providers, payers, and digital health companies, enabling predictive analytics at scale while protecting privacy.

Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.

Zebra Medical Vision is an Israel-based company that develops an imaging analytics platform for healthcare. The platform supplies clinicians with imaging research tools, provides advanced learning and computer-vision diagnostic algorithms for developers, and offers risk management and preventative care tools for providers. The company also offers researchers access to tools and datasets to accelerate the development of decision-support and diagnostic technologies. Founded in 2014 and headquartered in Shefayim, Zebra Medical Vision collaborates with partners such as USARAD Holdings and TELUS Ventures and has deployed its AI-enabled imaging analytics across hospitals worldwide.

Clara Health operates a software platform that facilitates participation in clinical trials for patients. Its technology enables users to discover and connect with relevant trials, streamlining the process from protocol design to site selection and adherence monitoring. The platform is designed to be patient-centric, allowing individuals to filter through available trials based on their specific needs and circumstances.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Lumiata is a predictive health analytics company that applies artificial intelligence to healthcare data to deliver real-time, patient-level predictions. It builds a medical graph to organize symptoms, diagnoses, procedures and medications, enabling risk-bearing organizations such as payers, hospital networks, and population health programs to forecast health trajectories, cost, and care needs. The Lumiata Risk Matrix provides time-based predictions with explanations of medical reasoning. The platform combines big data, clinical knowledge, and proprietary intellectual property drawn from over 120 million patient records to support use cases like underwriting and care management. Founded in 2013 and based in San Mateo, California, Lumiata serves providers, payers, and digital health companies, enabling predictive analytics at scale while protecting privacy.

Catalia Health Inc. is a San Francisco-based company that specializes in developing a cloud-based patient care management platform. Founded in 2014, Catalia Health combines artificial intelligence, psychology, and medicine to enhance patient engagement and provide valuable data to healthcare providers. Its innovative platform facilitates real-time communication with patients, addressing their ongoing healthcare issues through personalized conversations. These interactions occur via mobile apps, a web interface, and a patented interactive robotic coach, allowing healthcare professionals to monitor patient progress and adherence to treatment effectively. By delivering tailored medical support and psychological assistance, Catalia Health aims to improve patient outcomes within pharmaceuticals, healthcare systems, and assisted living facilities.

DocTalk Solutions India Private Limited, founded in 2016 and based in Mumbai, India, develops a mobile application aimed at enhancing communication between patients and their doctors. The application allows users to chat directly with their physicians, obtain prescriptions, and share medical reports, facilitating a more efficient healthcare experience. By providing a platform for remote consultations, DocTalk enables users to manage their health needs without the necessity of in-person visits, thereby streamlining access to medical advice and support.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.